Molecular pathways: Targeting RAC-p21-Activated serine-threonine kinase signaling in RAS-driven cancers

Clinical Cancer Research

Volumn 20, Issue 18, 2014, Pages 4740-4746

  Baker, Nicole M ^a,b   Chow, Hoi Yee ^c   Chernoff, Jonathan ^c   Der, Channing J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

P21 ACTIVATED KINASE; PROTEIN KINASE B;

ANIMAL; GENETICS; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; NEOPLASMS; P21-ACTIVATED KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84907445756     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1727     Document Type: Article

References (78)

1. Cox AD, Der CJ. Ras history: the saga continues. Small GTPases 2010; 1:2-27.
2. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging Ras back in the ring. Cancer Cell 2014;25:272-81.
3. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 2010;10:842-57.
4. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem 2011;3:1787-808.
5. Radu M, Semenova G, Kosoff R, Chernoff J. PAK signalling during the development and progression of cancer. Nat Rev Cancer 2014; 14:13-25.
6. King H, Nicholas NS, Wells CM. Role of p-21-activated kinases in cancer progression. Int Rev Cell Mol Biol 2014;309:347-87.
7. Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007;129:865-77.
8. Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 2005;6:167-80.
9. COSMIC. Catalogue of somatic mutations in cancer [database on the internet]. 2014. Hinxton (UK): Wellcome Trust Sanger Institute, Genome Research Limited; c2004 [updated 2014 Jul 1; cited 2014 Jun 9]. Available from: http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/
10. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
11. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007;129:957-68.
12. Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, Diefenbacher ME, et al. Requirement for interaction of PI3-kinase p110alpha with RAS in lung tumor maintenance. Cancer Cell 2013; 24:617-30.
13. ClinicalTrials.gov [database on the internet]. A service of the U.S. National Institutes of Health. 2014. Bethesda (MD): NIH [cited 2014 Jun 9]. Available from: http://clinicaltrials.gov
14. Malliri A, van der Kammen RA, Clark K, van der Valk M, Michiels F, Collard JG. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 2002;417:867-71.
15. Lambert JM, Lambert QT, Reuther GW, Malliri A, Siderovski DP, Sondek J, et al. Tiam1 mediates Ras activation of Rac by a PI(3)Kindependent mechanism. Nat Cell Biol 2002;4:621-5.
16. Welch HC, Coadwell WJ, Ellson CD, Ferguson GJ, Andrews SR, Erdjument-Bromage H, et al. P-Rex1, a PtdIns(3,4,5)P3-and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 2002;108:809-21.
17. Han J, Luby-Phelps K, Das B, Shu X, Xia Y, Mosteller RD, et al. Role of substrates and products of PI 3-kinase in regulating activation of Racrelated guanosine triphosphatases by Vav. Science 1998;279:558-60.
18. Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci 2005;118:843-6.
19. Archer H, Bar-Sagi D. Ras and Rac as activators of reactive oxygen species (ROS). Methods Mol Biol 2002;189:67-73.
20. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012; 150:251-63.
21. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006-14.
22. Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays 2007;29:356-70.
23. Bar-Sagi D, Feramisco JR. Induction of membrane ruffling and fluidphase pinocytosis in quiescent fibroblasts by ras proteins. Science 1986;233:1061-8.
24. Walsh AB, Bar-Sagi D. Differential activation of the Rac pathway by Ha-Ras and K-Ras. J Biol Chem 2001;276:15609-15.
25. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Molecular Cell Biol 1995;15:6443-53.
26. Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature 1995;374:457-9.
27. Joneson T, White MA, Wigler MH, Bar-Sagi D. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Science 1996;271:810-2.
28. Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, et al. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res 2007;67:8089-94.
29. Heid I, Lubeseder-Martellato C, Sipos B, Mazur PK, Lesina M, Schmid RM, et al. Early requirement of Rac1 in a mouse model o f pancreatic cancer. Gastroenterology 2011;141:719-30, 730 e1-7.
30. Samuel MS, Lourenco FC, Olson MF. K-Ras mediated murine epidermal tumorigenesis is dependent upon and associated with elevated Rac1 activity. PloS ONE 2011;6:e17143.
31. Westwick JK, Lambert QT, Clark GJ, Symons M, Van Aelst L, Pestell RG, et al. Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways. Mol Cell Biol 1997;17:1324-35.
32. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 2002;16:2045-57.
33. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species-and cell type-specific requirements for cellular transformation. Cancer Cell 2004;6:171-83.
34. Ahmed S, Prigmore E, Govind S, Veryard C, Kozma R, Wientjes FB, et al. Cryptic Rac-binding and p21(Cdc42Hs/Rac)-activated kinase phosphorylation sites of NADPH oxidase component p67(phox). J Biol Chem 1998;273:15693-701.
35. Arias-Romero LE, Chernoff J. A tale of two Paks. Biol Cell 2008;100: 97-108.
36. Ye DZ, Field J. PAK signaling in cancer. Cell Logist 2012;2: 105-16.
37. Chaudhary A, King WG, Mattaliano MD, Frost JA, Diaz B, Morrison DK, et al. Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr Biol 2000;10:551-4.
38. Coles LC, Shaw PE. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. Oncogene 2002;21:2236-44.
39. Sun H, King AJ, Diaz HB, Marshall MS. Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak. Curr Biol 2000;10:281-4.
40. Eblen ST, Slack JK, Weber MJ, Catling AD. Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes. Mol Cell Biol 2002;22: 6023-33.
41. Higuchi M, Onishi K, Kikuchi C, Gotoh Y. Scaffolding function of PAKin the PDK1-Akt pathway. Nat Cell Biol 2008;10:1356-64.
42. Chow HY, Jubb AM, Koch JN, Jaffer ZM, Stepanova D, Campbell DA, et al. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res 2012;72:5966-75.
43. Little AS, Smith PD, Cook SJ. Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene 2013;32:1207-15.
44. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012; 149:307-21.
45. Graves LM, Duncan JS, Whittle MC, Johnson GL. The dynamic nature of the kinome. Biochem J 2013;450:1-8.
46. Burris HA III. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013;71:829-42.
47. Tabusa H, Brooks T, Massey AJ. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. Mol Cancer Res 2013;11: 109-21.
48. Arias-Romero LE, Villamar-Cruz O, Huang M, Hoeflich KP, Chernoff J. Pak1 kinase links ErbB2 to beta-catenin in transformation of breast epithelial cells. Cancer Res 2013;73:3671-82.
49. Zhu G, Wang Y, Huang B, Liang J, Ding Y, Xu A, et al. A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells. Oncogene 2012;31:1001-12.
50. Ye DZ, Jin S, Zhuo Y, Field J. p21-activated kinase 1 (Pak1) phosphorylates BAD directly at serine 111 in vitro and indirectly through Raf-1 at serine 112. PLoS ONE 2011;6:e27637.
51. Misra UK, Deedwania R, Pizzo SV. Binding of activated alpha2-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK. J Biol Chem 2005;280:26278-86.
52. Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 2006;118:2703-10.
53. Vadlamudi RK, Li F, Barnes CJ, Bagheri-Yarmand R, Kumar R. p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. EMBO Rep 2004;5:154-60.
54. Webb BA, Eves R, Crawley SW, Zhou S, Cote GP, Mak AS. PAK1 induces podosomeformation in A7r5 vascularsmooth muscle cells in a PAK-interacting exchange factor-dependent manner. Am J Physiol Cell Physiol 2005;289:C898-907.
55. Vadlamudi RK, Barnes CJ, Rayala S, Li F, Balasenthil S, Marcus S, et al. p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B. Mol Cell Biol 2005;25:3726-36.
56. Banerjee M, Worth D, Prowse DM, Nikolic M. Pak1 phosphorylation on t212 affects microtubules in cells undergoing mitosis. Curr Biol 2002;12:1233-9.
57. Takahashi K, Suzuki K. Membrane transport of WAVE2 and lamellipodia formation require Pak1 that mediates phosphorylation and recruitment of stathmin/Op18 to Pak1-WAVE2-kinesin complex. Cell Signal 2009;21:695-703.
58. Morimura S, Takahashi K. Rac1 and Stathmin but not EB1 are required for invasion of breast cancer cells in response to IGF-I. Int J Cell Biol 2011;2011:615912.
59. Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci 2014;39:91-100.
60. Dharmawardhane S, Schurmann A, Sells MA, Chernoff J, Schmid SL, Bokoch GM.Regulation of macropinocytosis by p21-activated kinase-1. Mol Biol Cell 2000;11:3341-52.
61. Redelman-Sidi G, Iyer G, Solit DB, Glickman MS. Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. Cancer Res 2013;73:1156-67.
62. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013;497:633-7.
63. Lightcap CM, Kari G, Arias-Romero LE, Chernoff J, Rodeck U, Williams JC. Interaction with LC8 is required for Pak1 nuclear import and is indispensable for zebrafish development. PloS ONE 2009;4: e6025.
64. Qing H, Gong W, Che Y, Wang X, Peng L, Liang Y, et al. PAK1-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Tumour Biol 2012;33:985-94
65. Rayala SK, Molli PR, Kumar R. Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity. Cancer Res 2006; 66:5985-8.
66. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006;98:671-80.
67. Jagadeeshan S, Krishnamoorthy YR, Singhal M, Subramanian A, Mavuluri J, Lakshmi A, et al. Transcriptional regulation of fibronectin by p21-activated kinase-1 modulates pancreatic tumorigenesis. Oncogene. 2014 Feb[Epub ahead of print
68. Osada S, Izawa M, Koyama T, Hirai S, Ohno S. A domain containing the Cdc42/Rac interactive binding (CRIB) region of p65PAK inhibits transcriptional activation and cell transformation mediated by the Ras-Rac pathway. FEBS Lett 1997;404:227-33.
69. Tang Y, Yu J, Field J. Signals from the Ras, Rac, and Rho GTPases converge on the Pak protein kinase in Rat-1 fibroblasts. Mol Cell Biol 1999;19:1881-91.
70. Tang Y, Chen Z, Ambrose D, Liu J, Gibbs JB, Chernoff J, et al. Kinasedeficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Molecular Cell Biol 1997;17:4454-64.
71. Tang Y, Marwaha S, Rutkowski JL, Tennekoon GI, Phillips PC, Field J. Arole for Pak protein kinases in Schwann cell transformation. Proc Natl Acad Sci U S A 1998;95:5139-44.
72. Rudolph J, Crawford JJ, Hoeflich KP, Chernoff J. Inhibitors of the Ras superfamily G-proteins, Part B. p21-activated kinase inhibitors. In: Tamanoi F and Der CJ, editors. The enzymes, vol. Burlington, MA: Academic Press; 2013. p. 157-80.
73. Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A 2010;107:9446-51.
74. Guo C, McAlpine I, Zhang J, Knighton DD, Kephart S, Johnson MC, et al. Discovery of pyrroloaminopyrazoles as novel PAK inhibitors. J Med Chem 2012;55:4728-39.
75. Licciulli S, Maksimoska J, Zhou C, Troutman S, Kota S, Liu Q, et al. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. J Biol Chem 2013;288: 29105-14.
76. Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 2008; 15:322-31.
77. Viaud J, Peterson JR. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther 2009;8:2559-65.
78. Crawford JJ, Hoeflich KP,Rudolph J. p21-activated kinase inhibitors: a patent review. Expert Opin Ther Pat 2012;22:293-310.